GlobeNewswire Clinical StudiesOriginal article
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Phase 2positivediranersenPositive
AI Analysis
Summary
Biogen announced positive Phase 2 CELIA data for diranersen, an ASO therapy targeting tau in early Alzheimer's disease, demonstrating meaningful clinical efficacy and robust biomarker effects. The company plans to advance diranersen into confirmatory Phase 3 development based on consistent evidence from Phase 1b and Phase 2 studies.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Demonstrated meaningful clinical efficacy and robust tau reduction biomarker effects, providing Phase 2 proof of concept
Importance:7/10
Sentiment:
0.80
Alzheimer's diseasetauantisense oligonucleotidebiomarkerPhase 2 proof of conceptPhase 3 advancement
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 14, 2026 1:15 PM